Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price dropped 1.6% on Tuesday. The stock traded as low as $28.35 and last traded at $28.4050. 35,221,329 shares changed hands during mid-day trading, a decline of 11% from the average session volume of 39,712,441 shares. The stock had previously closed at $28.86.
Key Stories Impacting Pfizer
Investors following PFE have been watching these stories:
- Positive Sentiment: Pfizer has completed its acquisition of Metsera, giving it long-acting injectable obesity-drug candidates and a path back into a fast-growing market. The opportunity could bolster its pipeline, though Pfizer will need to compete with established leaders. Read More.
- Negative Sentiment: A comparison with Johnson & Johnson describes Pfizer’s revenue as more volatile across recent quarters, while J&J showed steadier growth. That contrast may weigh on confidence in the consistency of Pfizer’s business. Read More.
- Negative Sentiment: Options activity was characterized as moderately bearish, suggesting some traders are positioning cautiously around PFE. Read More.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on PFE. Sanford C. Bernstein reissued a "market perform" rating and set a $29.00 price target on shares of Pfizer in a research report on Thursday, November 12th. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday. Scotiabank increased their price objective on Pfizer from $33.00 to $35.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, November 4th. HSBC raised their target price on Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a research note on Thursday, September 10th. Finally, FBN Securities set a $34.00 target price on Pfizer in a research report on Friday, November 6th. Six equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $30.32.
View Our Latest Stock Analysis on Pfizer
Pfizer Stock Performance
The company has a market capitalization of $161.90 billion, a price-to-earnings ratio of 40.58, a price-to-earnings-growth ratio of 1.89 and a beta of 0.31. The stock's fifty day simple moving average is $28.81 and its 200-day simple moving average is $27.00. The company has a current ratio of 1.42, a quick ratio of 1.10 and a debt-to-equity ratio of 0.67.
Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.74 by $0.13. The firm had revenue of $16.58 billion during the quarter, compared to analysts' expectations of $15.85 billion. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. Pfizer's revenue for the quarter was down .4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.87 EPS. Analysts predict that Pfizer Inc. will post 3.04 EPS for the current year.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer's payout ratio is presently 245.71%.
Institutional Investors Weigh In On Pfizer
Institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its stake in shares of Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company's stock worth $132,365,000 after purchasing an additional 745,213 shares in the last quarter. Handelsbanken Fonder AB grew its position in Pfizer by 10.4% in the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company's stock worth $59,295,000 after acquiring an additional 232,528 shares in the last quarter. Leuthold Group LLC acquired a new position in shares of Pfizer during the 2nd quarter worth $4,887,000. Park National Corp OH raised its holdings in shares of Pfizer by 332.1% during the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company's stock valued at $5,829,000 after purchasing an additional 186,053 shares in the last quarter. Finally, 111 Capital bought a new position in shares of Pfizer during the 2nd quarter valued at $3,706,000. Hedge funds and other institutional investors own 68.36% of the company's stock.
Pfizer Company Profile
(
Get Free Report)
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company's products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.